Posted On: 11/12/2013 10:19:20 PM
Post# of 102452
$AMPE Up to date company activities and other important information about $AMPE
$AMPE
DD Notes ~ http://www.ddnotesmaker.com/AMPE
##### recent news/filings ~ source: finance.yahoo.com
Tue, 12 Nov 2013 12:00:00 GMT ~ Ampio AWOL With Knee-Pain Drug Data Disclosures
read full: http://www.thestreet.com/story/12104940/1/amp..._ven=YAHOO
*********************************************************
Fri, 08 Nov 2013 11:05:08 GMT ~ AMPIO PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/131108/ampe10-q.html
*********************************************************
Mon, 04 Nov 2013 13:11:47 GMT ~ Ampio announces positive results from SPRING study
read full: http://finance.yahoo.com/news/ampio-announces...47092.html
*********************************************************
Mon, 04 Nov 2013 13:00:00 GMT ~ Ampio Pharmaceuticals Reports Positive Results in the Extended Spring study of Osteoarthritis of the Knee Following a Single Intra-articular Injection of Ampion™
- GREENWOOD VILLAGE, Colo., Nov. 4, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced positive results from the eight (
week extension of the twelve (12) week SPRING study (clinicaltrials.gov NCT01839331) of Ampion™ for the treatment of osteoarthritis of the knee (OAK). In the Spring trial of 329 patients, statistically significant achievement of primary and key secondary endpoints following a single intra-articular injection into the knee of either 4 or 10 ml of Ampion™ versus the Saline vehicle control were demonstrated at 12 weeks as previously reported: Dr. Vaughan Clift, Ampio's Chief Regulatory Officer explained: "In the 329 patient Spring Study, both the efficacy and safety of the 4 mL and 10 mL doses were equivalent. Both doses were independently statistically significant, therefore Ampio selected 4 mL as the optimal dose for the extended study and followed the 97 patients who were administered either 4 mL Ampion™ or saline vehicle control for an additional 8 weeks. The results of this extended study should be read with the following two points in mind:
read full: http://finance.yahoo.com/news/ampio-pharmaceu...00496.html
*********************************************************
Mon, 28 Oct 2013 13:13:58 GMT ~ Dendreon, Zogenix, and Ampio Pharmaceuticals Could Be Big Movers Today
- Keep an eye on Dendreon, Zogenix, and Ampio -- they could make big moves during today's trading.
read full: http://www.fool.com/investing/general/2013/10...lnk0000001
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=AMPE&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=AMPE&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/AMPE/company-info
Ticker: $AMPE
OTC Market Place: Not Available
CIK code: 0001411906
Company name: Ampio Pharmaceuticals, Inc.
Company website: http://www.ampiopharma.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/AMPE/filings
Latest financials: http://www.otcmarkets.com/stock/AMPE/financials
Latest news: http://www.otcmarkets.com/stock/AMPE/news - http://finance.yahoo.com/q/h?s=AMPE+Headlines
Major holdings: http://data.cnbc.com/quotes/AMPE/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=AMPE+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/AMPE.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=AMPE
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Ampio+Pharmaceutic...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...als%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.ampiopharma.com
Alexa: http://www.alexa.com/siteinfo/http://www.ampiopharma.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.ampiopharma.com
http://www.pennystocktweets.com/stocks/profile/AMPE
##### last known share structure ~ source: otcmarkets.com
Market Value: $307,950,136 a/o Nov 11, 2013
Shares Outstanding: 37,102,426 a/o Aug 09, 2013
Float: 3,256,587 a/o Apr 26, 2011
Authorized Shares: 100,000,000 a/o Dec 31, 2010
Par Value: No Par Value
##### business description ~ source: otcmarkets.com
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The product pipeline includes new uses for previously approved drugs, some of which are now starting clinical trials, and new molecular entities (\
DD Notes ~ http://www.ddnotesmaker.com/AMPE
$AMPE
DD Notes ~ http://www.ddnotesmaker.com/AMPE
##### recent news/filings ~ source: finance.yahoo.com
Tue, 12 Nov 2013 12:00:00 GMT ~ Ampio AWOL With Knee-Pain Drug Data Disclosures
read full: http://www.thestreet.com/story/12104940/1/amp..._ven=YAHOO
*********************************************************
Fri, 08 Nov 2013 11:05:08 GMT ~ AMPIO PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/131108/ampe10-q.html
*********************************************************
Mon, 04 Nov 2013 13:11:47 GMT ~ Ampio announces positive results from SPRING study
read full: http://finance.yahoo.com/news/ampio-announces...47092.html
*********************************************************
Mon, 04 Nov 2013 13:00:00 GMT ~ Ampio Pharmaceuticals Reports Positive Results in the Extended Spring study of Osteoarthritis of the Knee Following a Single Intra-articular Injection of Ampion™
- GREENWOOD VILLAGE, Colo., Nov. 4, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced positive results from the eight (
week extension of the twelve (12) week SPRING study (clinicaltrials.gov NCT01839331) of Ampion™ for the treatment of osteoarthritis of the knee (OAK). In the Spring trial of 329 patients, statistically significant achievement of primary and key secondary endpoints following a single intra-articular injection into the knee of either 4 or 10 ml of Ampion™ versus the Saline vehicle control were demonstrated at 12 weeks as previously reported: Dr. Vaughan Clift, Ampio's Chief Regulatory Officer explained: "In the 329 patient Spring Study, both the efficacy and safety of the 4 mL and 10 mL doses were equivalent. Both doses were independently statistically significant, therefore Ampio selected 4 mL as the optimal dose for the extended study and followed the 97 patients who were administered either 4 mL Ampion™ or saline vehicle control for an additional 8 weeks. The results of this extended study should be read with the following two points in mind: read full: http://finance.yahoo.com/news/ampio-pharmaceu...00496.html
*********************************************************
Mon, 28 Oct 2013 13:13:58 GMT ~ Dendreon, Zogenix, and Ampio Pharmaceuticals Could Be Big Movers Today
- Keep an eye on Dendreon, Zogenix, and Ampio -- they could make big moves during today's trading.
read full: http://www.fool.com/investing/general/2013/10...lnk0000001
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=AMPE&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=AMPE&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/AMPE/company-info
Ticker: $AMPE
OTC Market Place: Not Available
CIK code: 0001411906
Company name: Ampio Pharmaceuticals, Inc.
Company website: http://www.ampiopharma.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/AMPE/filings
Latest financials: http://www.otcmarkets.com/stock/AMPE/financials
Latest news: http://www.otcmarkets.com/stock/AMPE/news - http://finance.yahoo.com/q/h?s=AMPE+Headlines
Major holdings: http://data.cnbc.com/quotes/AMPE/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=AMPE+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/AMPE.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=AMPE
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Ampio+Pharmaceutic...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...als%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.ampiopharma.com
Alexa: http://www.alexa.com/siteinfo/http://www.ampiopharma.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.ampiopharma.com
http://www.pennystocktweets.com/stocks/profile/AMPE
##### last known share structure ~ source: otcmarkets.com
Market Value: $307,950,136 a/o Nov 11, 2013
Shares Outstanding: 37,102,426 a/o Aug 09, 2013
Float: 3,256,587 a/o Apr 26, 2011
Authorized Shares: 100,000,000 a/o Dec 31, 2010
Par Value: No Par Value
##### business description ~ source: otcmarkets.com
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The product pipeline includes new uses for previously approved drugs, some of which are now starting clinical trials, and new molecular entities (\
DD Notes ~ http://www.ddnotesmaker.com/AMPE
(0)
(0)Scroll down for more posts ▼
